keyword
MENU ▼
Read by QxMD icon Read
search

New treatments for glaucoma

keyword
https://www.readbyqxmd.com/read/28101045/express-mini-shunt-as-a-treatment-alternative-for-medically-uncontrolled-steroid-induced-glaucoma-in-a-pediatric-patient
#1
Bonnie Nga Kwan Choy, Mandy Oi Man Wong, Jonathan Cheuk Hung Chan, Connie Hong Yee Lai, Jimmy Shiu Ming Lai
This case report illustrates the use of ExPRESS mini-shunt in a pediatric glaucoma patient. We describe the management of steroid-induced glaucoma with ExPRESS mini-shunt in a 9-year-old boy with allergic keratoconjunctivitis. The intraocular pressure of both of his eyes was uncontrolled with medical and laser treatment. Both eyes were treated with ExPRESS mini-shunt and mitomycin-C. Transient overfiltration with postoperative hypotony occurred in both eyes and resolved after 2 weeks. One year postoperatively, intraocular pressure was maintained below 21 mm Hg without medication in 1 eye...
September 2016: Case Reports in Ophthalmology
https://www.readbyqxmd.com/read/28088523/the-selective-cysteinyl-leukotriene-receptor-1-cyslt1r-antagonist-montelukast-regulates-extracellular-matrix-remodeling
#2
Jingli Peng, Hezheng Zhou, Guoping Kuang, Lilian Xie, Tao Tian, Ru Liu
Scar formation after filtration surgery of glaucoma is mainly caused by excessive synthesis of new extracellular matrix (ECM) and contraction of subconjunctival tissue mediated by human Tenon fibroblasts (HTFs) and the transforming growth factor (TGF-β1). Montelukast, a potent and specific cysteinyl leukotriene receptor 1 (cysLT1R) antagonist, is a licensed drug clinically used for the treatment of bronchial asthma. In this study, we investigated the effects of montelukast on the contractility of HTFs cultured in a three-dimensional collagen gel...
January 11, 2017: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/28076854/open-angle-glaucoma-drug-development-pipeline-during-the-last-20-years-1995-2015
#3
André Vicente, Sylvie Prud'homme, Joana Ferreira, Luís Abegão Pinto, Ingeborg Stalmans
OBJECTIVES: To analyse drug development for open-angle glaucoma during the last 20 years. METHODS: Research was performed by referring to clinical trials registered at the International Clinical Trials Registry Platform (ICTRP). A search for the condition "open-angle glaucoma" with the intervention "drug" was performed. We included trials registered from 01/01/1995 to 01/01/2015, only involving studies in phases 1, 2, and 3. Only studies resorting to novel treatment strategies (either novel drugs or yet-untested fixed associations of approved medication) were considered...
January 12, 2017: Ophthalmic Research
https://www.readbyqxmd.com/read/28048944/rho-kinase-inhibitors-a-patent-review-2014-2016
#4
Olivier Defert, Sandro Boland
The Rho-kinases (ROCK), ROCK1 and ROCK2, are potent, widespread biochemical modulators which have been extensively studied. Due to the involvement of ROCKs in multiple biological processes, ROCK inhibitors have pleiotropic actions and may be of relevance for a number of therapeutic applications. The drawback is however that their use might be limited by occurrence of side effects. Areas covered: Since the publication of the latest review in 2014, there have been significant advances in the field of ROCK inhibitors...
January 3, 2017: Expert Opinion on Therapeutic Patents
https://www.readbyqxmd.com/read/28039061/primary-angle-closure-glaucoma-what-we-know-and-what-we-don-t-know
#5
REVIEW
Xinghuai Sun, Yi Dai, Yuhong Chen, Dao-Yi Yu, Stephen J Cringle, Junyi Chen, Xiangmei Kong, Xiaolei Wang, Chunhui Jiang
Primary angle-closure glaucoma (PACG) is a common cause of blindness. Angle closure is a fundamental pathologic process in PAGC. With the development of imaging devices for the anterior segment of the eye, a better understanding of the pathogenesis of angle closure has been reached. Aside from pupillary block and plateau iris, multiple-mechanisms are more common contributors for closure of the angle such as choroidal thickness and uveal expansion, which may be responsible for the presenting features of PACG...
December 28, 2016: Progress in Retinal and Eye Research
https://www.readbyqxmd.com/read/28013525/interaction-of-primary-human-trabecular-meshwork-cells-with-metal-alloy-candidates-for-micro-invasive-glaucoma-surgery
#6
Wan Wendy Wang, Kelsey A Watson, S Jeffrey Dixon, Hong Liu, Amin Rizkalla, Cindy Ml Hutnik
BACKGROUND: Microinvasive glaucoma surgery (MIGS) is a relatively new addition to the glaucoma treatment paradigm. Small metallic stents are inserted into the trabecular meshwork in order to increase aqueous humour drainage. MIGS procedures are rapidly being adopted due to a more favourable side effect profile when compared to traditional surgery. Remarkably, this rapid rate of utilization has occurred without any published studies on the effect of metal alloys used in these stents on human trabecular meshwork cells (HTMCs)...
December 25, 2016: Clinical & Experimental Ophthalmology
https://www.readbyqxmd.com/read/28000166/current-perspectives-on-the-use-of-anti-vegf-drugs-as-adjuvant-therapy-in-glaucoma
#7
REVIEW
Vanessa Andrés-Guerrero, Lucía Perucho-González, Julián García-Feijoo, Laura Morales-Fernández, Federico Saenz-Francés, Rocío Herrero-Vanrell, Luis Pablo Júlvez, Vicente Polo Llorens, José María Martínez-de-la-Casa, Anastasios-Georgios P Konstas
The approval of one of the first anti-vascular endothelial growth factor (VEGF) agents for the treatment of neovascular age-related macular degeneration one decade ago marked the beginning of a new era in the management of several sight-threatening retinal diseases. Since then, emerging evidence has demonstrated the utility of these therapies for the treatment of other ocular conditions characterized by elevated VEGF levels. In this article we review current perspectives on the use of anti-VEGF drugs as adjuvant therapy in the management of neovascular glaucoma (NVG)...
December 20, 2016: Advances in Therapy
https://www.readbyqxmd.com/read/27966829/paediatric-eye-injuries-in-finland-helsinki-eye-trauma-study
#8
Anna-Kaisa Haavisto, Ahmad Sahraravand, Juha M Holopainen, Tiina Leivo
PURPOSE: To determine the current population-based epidemiology, treatment, use of resources and outcomes of children's eye injuries in Finland. METHODS: The study included all new patients, 16 years of age or under, with ocular or orbital traumas taken into care to the Helsinki University Eye Hospital (population base 1.5 million people) in 1 year. The follow-up period was 3 months. RESULTS: Two hundred and two children's eye injuries were treated...
December 14, 2016: Acta Ophthalmologica
https://www.readbyqxmd.com/read/27955999/neuroprotection-for-glaucoma-requirements-for-clinical-translation
#9
Leonard A Levin, Megan E Crowe, Harry A Quigley
Within the field of glaucoma research, neuroprotection is defined as slowing the functional loss in glaucoma by a mechanism independent of lowering of intraocular pressure. There is currently a great potential for research surrounding neuroprotection as it relates to glaucoma. Anatomical targets for neuroprotection should focus on upstream rather than downstream factors, and could include any part of the retinal ganglion cell, the glia, especially astrocytes or Muller cells, and vasculature. The great number of anatomical targets is exceeded only by the number of possible biochemical pathways and potential treatments...
December 9, 2016: Experimental Eye Research
https://www.readbyqxmd.com/read/27929541/non-amyloidogenic-effects-of-%C3%AE-2-adrenergic-agonists-implications-for-brimonidine-mediated-neuroprotection
#10
Shereen Nizari, Li Guo, Benjamin M Davis, Eduardo M Normando, Joana Galvao, Lisa A Turner, Mukhtar Bizrah, Mohammad Dehabadi, Kailin Tian, M Francesca Cordeiro
The amyloid beta (Aβ) pathway is strongly implicated in neurodegenerative conditions such as Alzheimer's disease and more recently, glaucoma. Here, we identify the α2 adrenergic receptor agonists (α2ARA) used to lower intraocular pressure can prevent retinal ganglion cell (RGC) death via the non-amyloidogenic Aβ-pathway. Neuroprotective effects were confirmed in vivo and in vitro in different glaucoma-related models using α2ARAs brimonidine (BMD), clonidine (Clo) and dexmedetomidine. α2ARA treatment significantly reduced RGC apoptosis in experimental-glaucoma models by 97...
December 8, 2016: Cell Death & Disease
https://www.readbyqxmd.com/read/27928879/minimally-invasive-glaucoma-surgery-as-primary-stand-alone-surgery-for-glaucoma
#11
REVIEW
Nathan M Kerr, Jing Wang, Keith Barton
Recently many new devices and procedures have been developed to lower intraocular pressure in a less invasive and purportedly safer manner than traditional glaucoma surgery. These new devices might encourage an earlier transition to surgery and reduce the long term commitment to topical glaucoma medications with their associated compliance and intolerance issues. While often seen as an adjunct to cataract surgery, a growing body of evidence suggests that primary MIGS may be a viable initial treatment option...
December 8, 2016: Clinical & Experimental Ophthalmology
https://www.readbyqxmd.com/read/27909796/-clinical-morphological-and-molecular-biological-characteristics-of-the-aging-eye
#12
M R R Böhm, H Thomasen, F Parnitzke, K-P Steuhl
BACKGROUND: The physiological aging of the eye is associated with loss of visual function. Age-related changes of the eye can result in ophthalmological diseases. The aim of this article is to display morphological, histological and molecular biological alterations of the aging eye. MATERIAL AND METHODS: A web-based search and review of the literature for aging of the visual system including cornea, lens, vitreous humor, retina, retinal pigment epithelium (RPE), choroidea and optic nerve were carried out...
December 1, 2016: Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
https://www.readbyqxmd.com/read/27906813/truncation-of-in-situ-baerveldt-glaucoma-drainage-device-for-treatment-of-late-persistent-postoperative-hypotony
#13
Philip P Chen
PURPOSE: To describe a new technique to treat late persistent hypotony after Baerveldt glaucoma drainage device surgery. METHODS: Review of 2 cases treated with in situ truncation of one or both wings of the Baerveldt device, combined with permanent but releasable tube occlusion. RESULTS: Two eyes with persistent hypotony underwent in situ truncation of one or both wings of the Baerveldt device with resolution of hypotony. Recurrence of elevated intraocular pressure (IOP) in both cases required reversal of tube occlusion, after which the IOP has remained both well controlled and sufficiently elevated to avoid complications of hypotony over 13 and 43 months...
November 30, 2016: Journal of Glaucoma
https://www.readbyqxmd.com/read/27898468/update-on-ciliary-body-laser-procedures
#14
Behzad Amoozgar, Eileen N Phan, Shan C Lin, Ying Han
PURPOSE OF REVIEW: There are currently various options available for glaucoma treatment procedures ranging from laser to penetrating to nonpenetrating surgeries. Innovations in glaucoma surgical therapeutics include features such as external application, focused tissue effects, and minimal manipulation as these factors all help lower the risk of side-effects in addition to increasing the success rate of the treatment. Traditional diode laser transscleral cyclophotocoagulation (TSCPC) is invasive and destructive...
November 25, 2016: Current Opinion in Ophthalmology
https://www.readbyqxmd.com/read/27898466/genetics-and-genetic-testing-for-glaucoma
#15
Matthew A Miller, John H Fingert, Daniel I Bettis
PURPOSE OF REVIEW: In recent decades, investigators have identified numerous genes and genetic factors that cause or contribute risk for glaucoma. These findings have increased our understanding of disease mechanisms, provided us with new diagnostic tools, and may allow for development of improved therapies for glaucoma. However, genetic testing is most useful when it is reserved for appropriate patients. The purpose of this article is to review key points and recent developments regarding the genetics and genetic testing for glaucoma and to provide recommendations for when genetic testing may be warranted...
November 25, 2016: Current Opinion in Ophthalmology
https://www.readbyqxmd.com/read/27897119/glaucoma-hot-topics-in-pharmacology
#16
Shiama I Balendra, Parth Arvind Shah, Mishank Jain, Andrzej Grzybowski, Maria Francesca Cordeiro
BACKGROUND: Glaucoma comprises a group of neurodegenerative diseases resulting in retinal ganglion cell death within the optic nerve head. It is projected to affect almost 80 million people worldwide by 2020. The condition's asymptomatic nature translates to over half of glaucoma sufferers being unaware of their condition. By the time of diagnosis, irreversible blindness is likely to have occurred. Prime areas of glaucoma research therefore include identification and optimization of risk factors for the disease, accurate and early diagnostic tools and novel therapeutic methods...
29, 2016: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/27895936/neovascular-glaucoma-a-review
#17
REVIEW
Gustavo B Rodrigues, Ricardo Y Abe, Camila Zangalli, Savio L Sodre, Flavia A Donini, Danilo C Costa, Andre Leite, Joao P Felix, Marcelo Torigoe, Alberto Diniz-Filho, Homero Gusmão de Almeida
Neovascular glaucoma (NVG) is a secondary glaucoma generally associated with poor visual prognosis. The development of new vessels over the iris and the iridocorneal angle can obstruct aqueous humor outflow and lead to increased intraocular pressure. The underlying pathogenesis in most cases is posterior segment ischemia, which is most commonly secondary to proliferative diabetic retinopathy or central vein retinal occlusion. The neovascularization process in the eye is driven by the events that alter the homeostatic balance between pro-angiogenic factors, such as the vascular endothelial growth factor and anti-angiogenic factors, such as the pigment-epithelium-derived factor...
2016: International Journal of Retina and Vitreous
https://www.readbyqxmd.com/read/27872861/danish-nationwide-data-reveal-a-link-between-diabetes-mellitus-diabetic-retinopathy-and-glaucoma
#18
Anna Horwitz, Beáta Éva Petrovski, Christian Torp-Pedersen, Miriam Kolko
Aims. To determine the association between treatment against diabetes mellitus (DM) and treatment with antiglaucomatous drugs in the entire Danish population and to investigate the comorbidity between DM and its complications with antiglaucomatous treatment. Methods. Retrospective nationwide cohort study with data over a 16-year follow-up period. The National Danish Registry of Medicinal Products Statistics was used to identify all claimed prescriptions for antiglaucomatous medication and DM drugs. ICD-10 classifications were furthermore used to identify comorbidities between antiglaucomatous medication and the DM complications, diabetic retinopathy (DR), and nephropathy...
2016: Journal of Diabetes Research
https://www.readbyqxmd.com/read/27871941/mimicking-the-ocular-environment-for-the-study-of-inflammatory-posterior-eye-disorders
#19
REVIEW
Nabeela K Dulull, Thilini R Thrimawithana, Faith A A Kwa
The common inflammatory posterior eye disorders, age-related degeneration and glaucoma often lead to irreversible vision loss. Current treatments do not target early stages or prevent disease progression. Consequently, the identification of biomarkers or early disease models that can accurately mimic the pathological processes involved is essential. Although none of the existing models can recapitulate all pathological aspects of these disorders, these models have revealed new therapeutic targets. Efforts to accurately phenotype eye disorders at various disease stages are warranted to generate a 'super' model that can replicate the microenvironment of the eye and associated pathological hallmarks effectively...
November 18, 2016: Drug Discovery Today
https://www.readbyqxmd.com/read/27857490/current-imaging-modalities-for-assessing-ocular-blood-flow-in-glaucoma
#20
REVIEW
Chirayu Mohindroo, Parul Ichhpujani, Suresh Kumar
: Glaucoma may be caused by an interplay of elevated intraocular pressure (IOP), vascular, genetic, anatomical, brain, and immune factors. The direct assessment of ocular hemodynam-ics offers promise for glaucoma detection, differentiation, and possibly new treatment modalities. All the methods currently in use to measure ocular blood flow have inherent limitations and measure different aspects of ocular blood flow. This review article attempts to provide detailed information on ocular perfu-sion pressure as well as an overview of the newly developed imaging technologies used to investigate ocular blood flow in glaucoma patients...
September 2016: Journal of Current Glaucoma Practice
keyword
keyword
85522
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"